280 related articles for article (PubMed ID: 25774916)
1. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients.
Pereira RC; Jüppner H; Gales B; Salusky IB; Wesseling-Perry K
PLoS One; 2015; 10(3):e0120856. PubMed ID: 25774916
[TBL] [Abstract][Full Text] [Related]
2. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone.
Pereira RC; Salusky IB; Bowen RE; Freymiller EG; Wesseling-Perry K
Bone; 2019 Oct; 127():626-634. PubMed ID: 31377240
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
5. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
Pereira RC; Juppner H; Azucena-Serrano CE; Yadin O; Salusky IB; Wesseling-Perry K
Bone; 2009 Dec; 45(6):1161-8. PubMed ID: 19679205
[TBL] [Abstract][Full Text] [Related]
6. Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23.
Sapir-Koren R; Livshits G
Biofactors; 2014; 40(6):555-68. PubMed ID: 25352227
[TBL] [Abstract][Full Text] [Related]
7. Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation.
Pereira RC; Valta H; Tumber N; Salusky IB; Jalanko H; Mäkitie O; Wesseling Perry K
PLoS One; 2015; 10(9):e0138156. PubMed ID: 26390291
[TBL] [Abstract][Full Text] [Related]
8. FGF-23 in bone biology.
Wesseling-Perry K
Pediatr Nephrol; 2010 Apr; 25(4):603-8. PubMed ID: 20012997
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.
Rhee Y; Bivi N; Farrow E; Lezcano V; Plotkin LI; White KE; Bellido T
Bone; 2011 Oct; 49(4):636-43. PubMed ID: 21726676
[TBL] [Abstract][Full Text] [Related]
10. Pigment epithelium-derived factor (PEDF) reduced expression and synthesis of SOST/sclerostin in bone explant cultures: implication of PEDF-osteocyte gene regulation in vivo.
Li F; Cain JD; Tombran-Tink J; Niyibizi C
J Bone Miner Metab; 2019 Sep; 37(5):773-779. PubMed ID: 30607618
[TBL] [Abstract][Full Text] [Related]
11. Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.
Wesseling-Perry K; Mäkitie RE; Välimäki VV; Laine T; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O
J Clin Endocrinol Metab; 2017 Jul; 102(7):2340-2348. PubMed ID: 28379384
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Dentin Matrix Protein 1 Enhances Fibroblast Growth Factor 23 in Calvaria in a Primary Hyperparathyroidism Model.
Nagata Y; Imanishi Y; Ohara M; Maeda-Tateishi T; Miyaoka D; Hayashi N; Kurajoh M; Emoto M; Inaba M
Endocrinology; 2019 May; 160(5):1348-1358. PubMed ID: 30916761
[TBL] [Abstract][Full Text] [Related]
13. [Osteocyte and DMP1].
Toyosawa S; Oya K; Sato S; Ishida K
Clin Calcium; 2012 May; 22(5):713-20. PubMed ID: 22549196
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice.
Miyagawa K; Yamazaki M; Kawai M; Nishino J; Koshimizu T; Ohata Y; Tachikawa K; Mikuni-Takagaki Y; Kogo M; Ozono K; Michigami T
PLoS One; 2014; 9(4):e93840. PubMed ID: 24710520
[TBL] [Abstract][Full Text] [Related]
15. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
17. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
[TBL] [Abstract][Full Text] [Related]
18. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
19. Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients.
Boltenstål H; Qureshi AR; Behets GJ; Lindholm B; Stenvinkel P; D'Haese PC; Haarhaus M
Calcif Tissue Int; 2019 Feb; 104(2):214-223. PubMed ID: 30406279
[TBL] [Abstract][Full Text] [Related]
20. Bone and heart health in chronic kidney disease: role of dentin matrix protein 1.
Martin A
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):297-303. PubMed ID: 31107286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
